917815-04-4

Basic information

• Product Name: N-({4-[(2R,3R)-3-{[(2R/S)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-isovaline
• Synonyms: N-({4-[(2R,3R)-3-{[(2R/S)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-isovaline
• CAS NO: 917815-04-4
• Molecular Weight: 794.029
• Mol File: 917815-04-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-({4-[(2R,3R)-3-{[(2R/S)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-isovaline(CAS DataBase Reference)
• NIST Chemistry Reference: N-({4-[(2R,3R)-3-{[(2R/S)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-isovaline(917815-04-4)
• EPA Substance Registry System: N-({4-[(2R,3R)-3-{[(2R/S)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-isovaline(917815-04-4)

Safety Data

• Hazardous Substances Data: 917815-04-4(Hazardous Substances Data)

Upstream product

• 917815-12-4 N-({4-[(2R,3R)-3-{[(2R/S)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycine 
• 4378-19-2 (S)-α-Methylvaline 
• 917815-14-6 N-({4-[(2R,3R)-3-{[(2R/S)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycine methyl ester 

Relevant articles and documents

NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS

Compounds of formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.